-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
DexCom's Income Statement
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$2.45 B | $2.91 B | $3.62 B | $4.03 B | $4.66 B |
| Cost of Revenue |
|
$768.00 M | $1.03 B | $1.33 B | $1.59 B | $1.86 B |
| Gross Profit |
|
$1.68 B | $1.88 B | $2.29 B | $2.44 B | $2.80 B |
| Research & Development |
|
$604.20 M | $484.20 M | $505.80 M | $552.40 M | $599.10 M |
| Selling,General & Administrative |
|
$810.50 M | $1.00 B | $1.19 B | $1.29 B | $1.29 B |
| Operating Expense |
|
$1.41 B | $1.49 B | $1.69 B | $1.84 B | $1.89 B |
| Operating Income |
|
$265.80 M | $391.20 M | $597.70 M | $600.00 M | $911.80 M |
| Net Income |
|
$216.90 M | $341.20 M | $541.50 M | $576.20 M | $836.30 M |
DexCom's Assets vs Liabilities & Equity
DexCom's Balance Sheet
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$2.73 B | $2.46 B | $2.72 B | $2.58 B | $2.00 B |
| Inventories |
|
$357.30 M | $306.70 M | $559.60 M | $542.60 M | $629.10 M |
| Total Current Assets |
|
$3.68 B | $3.67 B | $4.43 B | $4.30 B | $4.03 B |
| Property,Plant and Equipment |
|
$889.90 M | $1.14 B | $1.18 B | $1.40 B | $1.64 B |
| Goodwill |
|
$26.50 M | $25.70 M | $25.20 M | $22.80 M | $24.20 M |
| Total Assets |
|
$4.93 B | $5.39 B | $6.26 B | $6.48 B | $6.34 B |
| Total Liabilities |
|
$2.89 B | $3.26 B | $4.20 B | $4.38 B | $3.59 B |
| Retained Earnings |
|
$138.70 M | $479.90 M | $1.02 B | $1.60 B | $2.43 B |
| Total Shareholder Equity |
|
$2.04 B | $2.13 B | $2.07 B | $2.10 B | $2.75 B |
| Common Stock |
|
$400.00 K | $400.00 K | $400.00 K | $400.00 K | $400.00 K |
DexCom's Cash flow
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$102.00 M | $155.90 M | $186.00 M | $217.70 M | $251.80 M |
| Dividends Payout |
|
- | - | - | - | - |
| Capital Expenditures (Capex) |
|
-$389.20 M | -$364.80 M | -$236.60 M | -$358.80 M | -$363.50 M |
| Free Cash Flow (FCF) |
|
$53.30 M | $304.70 M | $511.90 M | $630.70 M | $1.08 B |
DexCom's Profitability
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$1.68 B | $1.88 B | $2.29 B | $2.44 B | $2.80 B |
| Gross Profit Margin (%) |
|
68.63% | 64.72% | 63.19% | 60.46% | 60.10% |
| Operating Income |
|
$265.80 M | $391.20 M | $597.70 M | $600.00 M | $911.80 M |
| Operating Income Margin (%) |
|
10.86% | 13.44% | 16.50% | 14.88% | 19.56% |
| Net Income |
|
$216.90 M | $341.20 M | $541.50 M | $576.20 M | $836.30 M |
| Net Income Margin (%) |
|
8.86% | 11.73% | 14.95% | 14.29% | 17.94% |
| EBITDA |
|
$377.50 M | $565.30 M | $916.70 M | $945.70 M | $1.16 B |
| EBITDA Margin (%) |
|
15.42% | 19.43% | 25.31% | 23.45% | 24.96% |
DexCom's Ratios
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
10.62% | 16.01% | 26.18% | 27.40% | 30.46% |
| Return on Assets (ROA) |
|
4.40% | 6.33% | 8.64% | 8.89% | 13.19% |
| Debt to Equity |
|
105.67% | 100.62% | 125.40% | 123.06% | 50.61% |
| Debt to total asset |
|
43.74% | 39.78% | 41.41% | 39.90% | 21.92% |
| Enterprise value to revenue |
|
21.66 | 15.67 | 13.78 | 8.29 | 5.66 |
| Enterprise value to EBITDA |
|
140.51 | 80.66 | 54.46 | 35.37 | 22.68 |
| Enterprise value |
|
$53.04 B | $45.60 B | $49.93 B | $33.45 B | $26.39 B |
| Tax Rate (%) |
|
15.54% | 12.69% | 23.78% | 18.73% | 23.16% |
Frequently Asked Questions
